Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h

Google maps

Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :

Pitt researchers to monitor resistance to HIV drugs in Africa

PITTSBURGH, Aug. 3, 2015 – Infectious diseases researchers from the University of Pittsburgh School of Medicine are leading a five-year, $5 million initiative to monitor drug resistance during the rollout of HIV prevention drugs in sub-Saharan Africa.   A cooperative agreement awarded by the U.S. Agency for International Development (USAID), will allow experts in...


Northwestern receives $17 million grant for HIV prevention research

Northwestern Medicine scientists have received a 5-year, $17.5 million grant from the National Institutes of Health (NIH) for an interdisciplinary project that aims to invent, develop and test an implantable drug delivery system to protect high-risk individuals from HIV infection for up to a year at a time. The Sustained Long-Acting Protection Against HIV (SLAP HIV) program, funded by...


Highlighting the need for a science and people centred approach in the AIDS response

The AIDSImpact 2015 conference held in Amsterdam from 28 to 31 July has heard appeals for the better integration of behavioural and psychosocial scientific research in the AIDS response. Researchers from around the world presented the latest findings in behavioural and psychosocial science related to HIV prevention, treatment and care, focusing both on the global level and on specific...


Source Source: UNAIDS

Achillion announces that Janssen has initiated a Phase I study to evaluate the effect of simeprevir and odalasvir (ACH-3102) on AL-335 pharmacokinetics

NEW HAVEN, Conn., Aug. 03, 2015 -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102) on the pharmacokinetics of AL-335 in healthy volunteers. This phase I study is an...


Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme

Interferon-free treatment using daclatasvir ( Daklinza ) and sofosbuvir ( Sovaldi ), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and HCV co-infection and advanced liver disease, according to a presentation at the Eighth International AIDS Society Conference on HIV Pathogenesis, Treatment and...


Source Source: Aidsmap